Policies and Practices to Address Cancer's Long-Term Adverse Consequences

被引:3
作者
Bradley, Cathy J. [1 ]
Kitchen, Sara [1 ]
Bhatia, Smita [2 ]
Bynum, Julie [3 ]
Darien, Gwen [4 ]
Lichtenfeld, J. Leonard [5 ]
Oyer, Randall [6 ]
Shulman, Lawrence N. [7 ]
Sheldon, Lisa Kennedy [8 ]
机构
[1] Univ Colorado, Canc Ctr, Dept Hlth Syst Management & Policy, 13001 E 17th Pl, Aurora, CO 80045 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA
[4] Natl Patient Advocate Fdn, Washington, DC USA
[5] Jasper Hlth, New York, NY USA
[6] Penn Med Lancaster Gen Hlth, Lancaster, PA USA
[7] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[8] St Joseph Hosp, Nashua, NH USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2022年 / 114卷 / 08期
基金
美国国家卫生研究院;
关键词
FINANCIAL HARDSHIP; YOUNG-ADULTS; HEALTH; SURVEILLANCE; ADOLESCENTS; SURVIVORS; SERVICES; RISK; RACE;
D O I
10.1093/jnci/djac086
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As cancer detection and treatment improve, the number of long-term survivors will continue to grow, as will the need to improve their survivorship experience and health outcomes. We need to better understand cancer and its treatment's short- and long-term adverse consequences and to prevent, detect, and treat these consequences effectively. Delivering care through a collaborative care model; standardizing information offered to and collected from patients; standardizing approaches to documenting, treating, and reducing adverse effects; and creating a data infrastructure to make population-based information widely available are all actions that can improve survivors' outcomes. National policies that address gaps in insurance coverage, the cost and value of treatment and survivorship care, and worker benefits such as paid sick leave can also concurrently reduce cancer burden. The National Cancer Policy Forum and the Forum on Aging, Disability, and Independence at the National Academies of Sciences, Engineering, and Medicine sponsored a virtual workshop on "Addressing the Adverse Consequences of Cancer Treatment," November 9-10, 2020, to examine long-term adverse consequences of cancer treatment and to identify practices and policies to reduce treatment's negative impact on survivors. This commentary discusses high-priority issues raised during the workshop and offers a path forward.
引用
收藏
页码:1065 / 1071
页数:7
相关论文
共 62 条
  • [1] Adams Lauren, 2019, EGEMS (Wash DC), V7, P41, DOI 10.5334/egems.311
  • [2] Understanding and addressing social determinants to advance cancer health equity in the United States: A blueprint for practice, research, and policy
    Alcaraz, Kassandra, I
    Wiedt, Tracy L.
    Daniels, Elvan C.
    Yabroff, K. Robin
    Guerra, Carmen E.
    Wender, Richard C.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2020, 70 (01) : 31 - 46
  • [3] Implementing personalized pathways for cancer follow-up care in the United States: Proceedings from an American Cancer Society-American Society of Clinical Oncology summit
    Alfano, Catherine M.
    Mayer, Deborah K.
    Bhatia, Smita
    Maher, Jane
    Scott, Jessica M.
    Nekhlyudov, Larissa
    Merrill, Janette K.
    Henderson, Tara O.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2019, 69 (03) : 234 - 247
  • [4] American Cancer Society, EM MENT HLTH MOOD CH
  • [5] American Cancer Society, 2 CANC REL TREATM
  • [6] American Society of Clinical Oncology, LONG TERM SID EFF CA
  • [7] [Anonymous], 2024, MedWatch: The FDA safety information and adverse event reporting program
  • [8] [Anonymous], ONC CAR MOD
  • [9] [Anonymous], Surveillance, Epidemiology, and End Results Program
  • [10] Modifiable Risk Factors and Major Cardiac Events Among Adult Survivors of Childhood Cancer
    Armstrong, Gregory T.
    Oeffinger, Kevin C.
    Chen, Yan
    Kawashima, Toana
    Yasui, Yutaka
    Leisenring, Wendy
    Stovall, Marilyn
    Chow, Eric J.
    Sklar, Charles A.
    Mulrooney, Daniel A.
    Mertens, Ann C.
    Border, William
    Durand, Jean-Bernard
    Robison, Leslie L.
    Meacham, Lillian R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3673 - +